

Supplementary Figure S1: FICZ does not affect the viability of HaCaT keratinocytes.

The viability of HaCaT cells treated with DMSO (0.1%, control) or FICZ (1, 10, or 100 nM or 1 or 10 μ M) for 6 or 24 h was assessed by using a WST-8 formazan-based method. Data are presented as means ± standard deviation (n = 5 per group).



Scale bar = 200 µm Green: AHR Blue: DAPI

Supplementary Figure S2: FICZ induces cytoplasmic to nuclear translocation of AHR. HaCaT cells were treated with DMSO (0.1%, control) or FICZ (1 and 100 nM) for 6 h and were immunostained with AHR. AHR was mainly localized in the cytoplasm in DMSO-treated control, while its nuclear translocation was induced by FICZ even at a concentration of 1 nM (arrows).



Supplementary Figure S3: FICZ induces intracellular glutathione (GSH) reduction.

HaCaT cells were treated with DMSO (0.1%, control) or FICZ (1, 10, 100 or 1000 nM) for 6 h and analyzed by GSH reduction assay. FICZ (10 to 1000 nM) did reduce the intracellular level of glutathione, implicating the production of ROS. Data are presented as means \pm standard deviation (n = 3 per group).



Supplementary Figure S4: Expression of proinflammatory cytokine mRNAs in keratinocytes treated with FICZ (100 nM).

Expression of *IL8, TNF, IL36A, IL36B,* and *IL36G* in the same sample as in Figure 4 was measured by qRT-PCR. Data are presented as means \pm standard deviation (n = 3 per group).



Supplementary Figure S4: FICZ activates NF-κB signaling.

HaCaT cells were treated with DMSO (0.1%, control) or FICZ (100 nM) and nuclear translocation of NF κ B p65 was evaluated by western blot. Representative image of bands (left panel) and density of nuclear NF- κ B p65 relative to DMSO-treated control (right panel) are shown. Nuclear Lamin B1 protein was used as internal control. Data are presented as means ± standard deviation (n = 3 per group).

Supplementary Figure S6



Supplementary Figure S6: FICZ induces CYP1A1 and ROS production in normal human keratinocytes.

Normal human epidermal keratinocytes (NHEKs) were (a) treated with DMSO (0.1%, control) or FICZ (100 nM) for 2, 4 and 6 h, or were (b) transfected with control siRNA or AHR siRNA, further treated with DMSO (0.1%) or FICZ (100 nM), and assessed for the expression of *CYP1A1* mRNA. (c) NHEKs were irradiated with UVB (30 mJ/cm²) or treated with FICZ (100 nM) and ROS production at 6 h-post treatment was evaluated by flow cytometry. Representative image of histogram (left panel) and mean fluorescence intensity of DCF (right panel) are shown. Data are presented as means ± standard deviation (n = 3 per group).